A retrospective cohort in the TriNetX US network compared 2,423 matched pairs of adults with obesity and asthma, on GLP-1 therapy or other weight-management drugs. Over one year, recorded asthma exacerbation occurred in 1.7% of the GLP-1 arm as compared to 4.0% of the comparator arm. Emergency or critical-care use was 7.1% as compared to 13.0%, although the authors state that residual confounding precludes causal inference.
Why it is interesting: A respiratory outcome for GLP-1 therapy from routine care, in a design that cannot separate effect from selection.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.